FDA gets power to reject drug-approval challenges on vague 'delay' grounds

What it does

This bill amends FDA drug-approval rules to make it easier for the FDA to reject petitions that appear designed primarily to delay generic or biosimilar drug approvals. It tightens the timeline for filing such petitions (60 days from when information became known), gives the FDA explicit authority to deny delay-tactic petitions based on factors like late submission, serial filings, or lack of supporting data, and requires the FDA to report to Congress on petition activity and any delays caused. The bill also bars citizens from suing the FDA over drug approvals unless they first exhaust the petition process and meet strict timing rules.

Why we flagged it

The bill's operative mechanism is to restrict the FDA's consideration of petitions that delay generic/biosimilar approvals and to bar citizens from suing unless they exhaust administrative remedies on a tight timeline. The stated purpose is to speed drug approvals; the mechanism is procedural gatekeeping that narrows citizens' access to the courts.

What the text implies

• The bill empowers the FDA to deny petitions based on subjective factors (e.g., 'unreasonable length of time,' 'close in time to patent expiration') without defining 'unreasonable' or 'close,' creating discretion that could be applied to suppress legitimate scientific objections.
• Requirement that petitioners submit all information and arguments in the petition or lose the right to sue bars incremental discovery and may force premature disclosure of litigation strategy.
• FTC referral for 'delay' petitions (Section 505(q)(1)(E)(iii)) creates a new enforcement pathway that could chill legitimate petitioning by competitors, especially smaller firms.
• Reporting requirement quantifies 'delay caused by petitions' but does not require FDA to report on petitions that raised valid safety or efficacy concerns, potentially obscuring the suppression of legitimate objections.
• The 60-day filing window and 'not more than 60 days' certification requirement may bar petitions based on information that emerges after market entry or post-approval adverse events.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from faster generic and biosimilar drug approvals, which typically lower prices and expand access. However, the bill restricts citizens' and competitors' procedural rights to petition the FDA and sue over approvals, potentially foreclosing legitimate safety or scientific objections if they are filed late or deemed part of a delay strategy. The balance depends on whether the procedural restrictions are applied narrowly (protecting only frivolous delay tactics) or broadly (blockin

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• large pharmaceutical companies with approved drugs facing generic competition

Named in the bill

FDA (Food and Drug Administration), FTC (Federal Trade Commission), generic drug manufacturers, biosimilar manufacturers, pharmaceutical companies, Section 505(b)(2) applicants (generic drugs), Section 505(j) applicants (biosimilars), Section 351(k) applicants (Public Health Service Act biosimilars)

Where it stands

1 cosponsor: 1 Republicans.

• May 19, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 19, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $590,000 in lobbying spend. A filing names 40 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Eric Sorensen, the sponsor, reported $905,648 in PAC receipts in the 2026 cycle.

• Blood Cancer United (fka the Leukemia & Lymphoma Society) — $590,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.